Cardiac MRI-Normal Reference Group Testing in Women

Condition: Microvascular coronary dysfunction

Eligibility

Key Inclusion Criteria

  • Women without signs and symptoms of myocardial ischemia (chest pain, abnormal stress testing, abnormal noninvasive testing)
  • No cardiac risk factors by Framingham/NCEP criteria, age and matched to the coronary microvascular dysfunction population
  • Normal exercise stress test

Key Exclusion Criteria

  • Contraindications to CMR testing (metal devices in chest, claustrophobia, known angioedema)
  • Contraindication to Adenosine or Lexiscan (regadenoson) including heart block (second and third degree) and sinus node disease, significant COPD/asthma, or systemic hypotension (< 90 mmHg)
  • Contraindication to Dobutamine including severe systemic hypertension (≥ 220/120 mmHg), unstable angina, significant aortic valve stenosis, complex cardiac arrhythmia including uncontrolled atrial fibrillation, hypertrophic obstructive cardiomyopathy, myocarditis, endocarditis, pericarditis, or uncontrolled congestive heart failure
  • Contraindication to gadolinium (renal impairment)
  • Any renal disease
  • Pregnant and lactating women
  • Inability to perform exercise, e.g., orthopedic limitations
  • Allergy to animal dander

Full Study Name

Cardiac Magnetic Resonance Imaging Normal Reference Control Group Testing – Ancillary Study to Coronary Endothelial Function and Microvascular Disease in Women (IRB no. 11753)

Summary

The purpose of this study is to understand how to apply cardiac magnetic resonance imaging (CMR) to women with small artery heart disease by looking at the CMRs of women without heart disease. Women with no known heart disease or heart disease risk factors will be recruited for the study.


Principal Investigator

C. Noel Bairey Merz, MD

Co-Investigators

Daniel Berman, MD
Chrisandra Shufelt, MD
Janet Wei, MD

Contact